Targeting important unmet medical needs

Second Half and Full Year 2021 Earnings Conference Call

April 12, 2022

Forward-Looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' (formerly Auris Medical) strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2021, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

2021 – Year of Transformation

- Laid groundwork to re-position the business through a key strategic shares-based acquisition (Trasir) to enter the RNA therapeutics market

- Continued to progress non-RNA legacy programs toward achieving key value-enhancing catalysts in Q2-22 and beyond

- Planned divestiture or spin-off of legacy business targeted for H2-22

- Unlock more intrinsic value from the legacy business and become a pure-play RNA therapeutics company

Pivot Towards RNA Therapeutics

Aim to become the leading company for extrahepatic RNA therapeutics

- Versatile peptide-based platform
  - OligoPhore™ (siRNA Payloads)
  - SemaPhore™ (mRNA Payloads)
- KRAS-driven cancer selected as first therapeutic indication for OligoPhore™ platform
- Exploring further potential applications

Global mRNA Therapeutics Market Growth



Current Challenges

- Delivery into target cells and tissues has proved to be a major challenge as RNA is inherently unstable and tends to show poor cellular uptake
- Various delivery technologies have been developed to address these challenges
- While there has been substantial progress with delivery of RNA therapeutics to the liver, **other target tissues and organs have remained difficult to reach**
- Another challenge has been the low amount of RNA payload that becomes available within the cells, which has been reported at 1-2% only
- **These challenges have clearly prevented more widespread adoption of RNA therapeutics**

How OligoPhore™ with siRNA Payloads SemaPhore™ with mRNA Payloads Work

The peptide-based OligoPhore™ / SemaPhore™ technology enabling safe and effective delivery of RNA payloads with systemic administration:

- *Stability:* RNA complexed in nanoparticle format for, and only released inside of cells after uptake
- *Extrahepatic delivery:* not sequestered in liver, but permeates inflamed pathological tissues
- *Endosomal escape:* pH-dependent nanoparticle disassembly, followed by full release of RNA into cytoplasm
- *Selectivity:* silences molecular targets in diseased tissues only
- *Safety:* no cellular or adaptive immune responsivity to nanoparticle components or RNA after multiple serial doses, and no organ toxicities in mice

Phore = Greek fo agent, bearer
Sema = Greek for sign, message

Summary of OligoPhore™ Mechanism of Action



Hou KK et al. A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. Biotechnol. Adv. 2015; 33(6 Pt 1): 931-40.

RNA Therapeutics Strategy Based on Two Pillars

1. **Developing RNA therapeutics demonstrate the clinical proof of concept for OligoPhore™ / SemaPhore™ technology platform**

   - Published new in vivo data ATLL and abdominal aortic aneurysm
   - Selected KRAS-driven cancers - first indication for drug development
   - Initiated a preclinical development program for AM-401
   - Aiming for an FDA IND in 2023 to be followed by a clinical proof-of-concept study in humans

2. **Leverage technology platform through partnering**
   - Aim to leverage platform through collaborations with other biopharmaceutical companies and the out-licensing of technology
   - Intend to become a delivery platform company

Key New Hires To Grow RNA Therapeutics

Samuel Wickline |MD

Chief Scientific Officer

Founder of Trasir Therapeutics and lead inventor of the OligoPhore / SemaPhore technology. Prof. of Cardiovascular Sciences, Molecular Physiology and Pharmacology, Medical Engineering at USF Former Prof. of Medicine, Physics, Biomedical Engineering, Cell Biology and Physiology at Wash U

Covadonga Pañeda |Ph.D.

Chief Development Officer

18 years experience in FDA/EMA drug development, non-clinical and clinical study design and regulatory submissions, incl. 7 years in ophthalmology RNAi

Developments in the non-RNA Legacy Business

Laying Foundations for Long Term Growth with 2 Nasal Spray Programs: Bentrio and AM-125

Protects

as a physical barrier
the nasal mucosa

Traps

airborne particles through
electrostatic effects

Humidifies

the nasal mucosa and thus
aids its functionality

Protects for ≥ 3 hours

Gel designed for extended
nasal residence time

Bentrio Clinical Study Developments (in Allergens)

Positive results from first clinical trial in allergic rhinitis in 2Q of 2021

- Significant reduction in nasal symptoms over four hours of controlled exposure to grass pollen
- In Canada, initiated a house dust-mite challenge study with allergic rhinitis patients, expected data read-outs in 2Q of 2022
- In Australia, the NASAR trial ongoing with patients who are naturally exposed to seasonal allergens is expected to report trial data in either Q4-22 or Q1-23

Bentrio Clinical Study Developments (in Viral)

Significantly lowers infectious viral titer when applied <u>prior to, or after,</u> infection with SARS-CoV-2, including the Delta and Omicron variants.

- Started the randomized controlled COVAMID trial in Bulgaria last month in March 2022
- Enrollment has been progressing swiftly so far and may complete the study in the third quarter of 2022

Bentrio Commercialization

3Q 2021 launched Bentrio commercially in Germany and Austria, via online pharmacies, followed by "brick and mortar" pharmacies starting late in 4Q 2021

- 1Q 2022, revenues up, approximately 2.5x FY21.
- Received the first orders from distributors and expects revenues from Bentrio to accelerate with further marketing clearances and respective product launches.
- Nuance Distributor, Asia, paid CYTO USD $1M up front.
- May receive development and commercial milestones up to $22.5 million and, upon production transfer, staggered royalty on net sales at a high-single to low-double-digit percentage.
- Created OTC Consumer Health business unit to support further growth, headed by industry veteran Jean Lachance starting next month.

Bentrio Positive Customer Reviews

"For many years I have been suffering from allergic rhinitis and sinusitis and tried out many different treatments – but without success. Thanks to Bentrio I could significantly reduce the irritation of my nasal mucosa."

"Using Bentrio, my sneezing is almost zero now and I am no longer blowing my nose every ten minutes."

Current Bentrio Markets

- German speaking European countries have been primary test markets.
- Plan to market and distribute Bentrio through established distributors leveraging their expertise and economies of scale in OTC consumer health markets worldwide.
- Established marketing and distribution agreements covering more than 20 international markets with ongoing discussions to expand into other countries and geographic regions.
- To date, Bentrio has been cleared for sale in the countries of the European Union, Switzerland, UK, Singapore, and Malaysia.
- For the US market, filed with the FDA in October 2021 a 510(k) application for premarket clearance of Bentrio in the allergy indication. The review of the submission is still ongoing at this point.

Advancements in AM-125 Program to Treat Vertigo



Our Neurotology Business

- Rx nasal spray (AM-125)
- Reformulated betahistine for vertigo
- Superior bioavailability vs. oral form
- Global market size (oral, ex US) = $450 mm

AM-125 Clinical Developments

- After COVID-19 delay, completed enrollment of Part B TRAVERS Phase 2 clinical trial in March 2022.
- Top-line data from the trial are expected to be announced this quarter, 2Q 2022.
- An interim analysis of Part A of the trial demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125.
- At the highest dose of 20 mg, AM-125-treated patients demonstrated, on average, a 2.6-fold improvement in Tandem Romberg test performance from baseline to six weeks, compared to those who received placebo.
- This positive outcome was supported by similar improvements in additional efficacy measures, including additional objectives as well as clinician- and patient-reported outcomes.
- Currently preparing the submission of an IND to the FDA for the next steps in the clinical development of AM-125.

CYTO AM-125 Potential and Market Plan

Intranasal formulation of betahistine, widely used for decades in tablet form as a vestibular stimulant and **standard of care in vertigo treatment and management around the world – Except US**

- Vestibular dysfunction affects more than one-third of the U.S. population 40 years of age and older.
- Circumvents first-pass metabolism, AM-125 shown 5-to-29 times higher bioavailability than orally administered betahistine.
- If approved and marketed in the US and globally, CYTO believes market potential could reach $1 billion or more.
- Intends to pursue distribution partnering opportunities as more scalable model than Company distribution and marketing.

Financial Review and Forecast

Second Half 2021 – Profit & Loss

Select data from profit and loss account (in CHF 1,000s)

	2H 2021	2H 2020
Research and Development	5,545	1,978
Sales and Marketing	1,498	-
General and Administrative	1,884	1,059
Operating Loss	10,644	2,862
Net Loss	10,636	5,542
Net Loss per Share (CHF)	0.76	0.75

Full Year 2021 Financial Update – Profit & Loss

Select data from profit and loss account (in CHF 1,000)

	December 31, 2021	December 31, 2020
Research and Development	8,939	2,863
Sales and Marketing	1,498	-
General and Administrative	4,947	2,594
Operating Loss	17,099	5,283
Net Loss	17,390	8,200
Net Loss per Share (CHF)	1.31	1.36
Average weighted number of shares outstanding	13,246	6,014

Financial Update – Balance Sheet

Select data from balance sheet (in CHF 1,000)

	December 31, 2021	December 31, 2020
Cash and Cash Equivalents	1,000	11,259
Total Assets	18,839	20,799
Total Liabilities	6,134	4,029
Shareholders' Equity	12,704	16,770

Financings

- In 1Q 2022, raised CHF 5 million from FiveT Investment Management Ltd. through a convertible loan agreement
- The loan is convertible into common shares of stock at USD $1.95 per share
- Interest rate of 10% p.a. and will mature on February 8, 2023, if not converted by FiveT or pre-paid by CYTO
- Received USD $1 million as an upfront payment from Nuance Pharma

Cash Requirements for FY 2022

- Expect total cash requirements to be in the range of CHF 11 to 13 million
- Strategic repositioning: deprioritized development programs in tinnitus (Keyzilen®), hearing loss (Sonsuvi®) and antipsychotic induced weight gain (AM-201) and have written off all related intangible assets in 2021.
- Can draw upon cash position as well as equity line with Lincoln Park Capital and the “at-the-market” program with A.G.P.
- Other sources of funding may arise from planned spin-off or divestiture of all or parts of legacy business in 2H-22

Clinical Development Recap

Key Catalysts

- Expect read-outs on house dust mite challenge study with allergic rhinitis patients in the **second quarter of this year**
- Top line data from AM-125 TRAVERS Phase 2 is anticipated in the **current, second quarter of 2022**
- Preparing the **submission of an IND to the FDA for the next steps** in the clinical development of the AM-125 program for vertigo
- Seasonal allergic rhinitis NASAR clinical trial is expected to report top line data in **fourth quarter of 2022 or first quarter of 2023**
- COVAMID trial with Bentrio in acute COVID-19 may be **completed in 3Q 2022**
- In the RNA-based business, plan to submit an IND to the **FDA in 2023** for KRAS-driven cancer treatment using RNA therapeutics
- Expect FDA feedback on Bentrio 510(k) submission

APPENDIX

Leadership Team

Thomas Meyer |PhD

CEO and Chairman

Founder Auris Medical
14 years with Disetronic Group
incl. CEO and BoD member
>20% sales CAGR
$3 bn market cap

Samuel Wickline |MD

Chief Scientific Officer

Prof. of Cardiovascular Sciences, Molecular Physiology and Pharmacology,
Medical Engineering at USF
Former Prof. of Medicine, Physics, Biomedical Engineering, Cell Biology and Physiology at Wash U

Covadonga Pañeda |MD

Chief Development Officer

18 years experience in FDA/EMA drug development, non-clinical and clinical study design and regulatory submissions, incl. 7 years in ophthalmology RNAi

Marcel Gremaud |CPA

Chief Financial Officer

~30 years' experience
in controlling and accounting
in international pharma companies
and start-ups

2021 Financial Highlights

Key Figures (CHF, 1,000, except per share data)	12M 2021	12M 2020
Operating Expenses	15,384	5,457
Net Loss	17,390	8,200
Per Share	1.31	1.36
Total Liabilities	6,134	4,029
Shareholder's Equity	12,704	16,770

Shareholders' Equity: $12.7 Million

On February 4, 2022, closed a debt financing for CHF 5 million at an interest rate of 10% that matures 12 months from proceeds' disbursement

Contact

Contacts:

Thomas Meyer, PhD

Chief Executive Officer

thm@altamiratherapeutics.com